Benzinga··Not SpecifiedQuince Therapeutics Acquires Orphai, Raises $187M to Advance Rare Lung Disease Pipeline
Quince Therapeutics acquired Orphai Therapeutics and secured $187 million in private placement funding to develop LAM-001 for rare pulmonary diseases through 2028.
QNCXacquisitionprivate placement